

**Minutes of the December 9, 2011
Pharmacy & Therapeutics (P&T) Committee Meeting
SD Department of Social Services, Medical Services Division**

Members present

Rick Holm, MD; Debra Farver, PharmD; Dana Darger, RPh; Timothy Soundy, MD; Bill Ladwig, RPh; James Engelbrecht, MD; Michelle Baack, MD; Mikel Holland, MD; Kelly Oehlke, PharmD; Lenny Petrick, PharmD

DSS staff present

Mike Jockheck, RPh

HID staff present

Candace Rieth, PharmD

Administrative Business

The P&T meeting was called to order by D. Darger at approximately 1:00pm. Introductions of new committee members commenced. The minutes of the September 9, 2011 meeting were presented. D. Farver made a motion to approve. R. Holm seconded the motion. The motion was approved unanimously.

Prior Authorization Update and Statistics

C. Rieth presented an overview of the prior authorization (PA) activity for October 2011. There were a total of 1,783 PAs processed in the month of October, with 98.49% of those requests responded to in less than 8 hours. There were 1,495 (84%) requests received electronically and 288 (16%) requests received by fax.

Analysis of the Top 15 Therapeutic Classes

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 07/01/2011 – 09/30/2011. The top five classes were antipsychotics, cerebral stimulants, amphetamines, adrenals, and leukotriene modifiers. The top 15 therapeutic classes make up 40.37% of total claims. C. Rieth also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 12.76% of total claims.

Medications used to treat Hepatitis C Review

The committee placed Incivek and Victrelis on prior authorization at the September meeting. C. Rieth presented the prior authorization form. L. Kolodny, representing Merck, spoke regarding Victrelis. A motion was made by D. Farver to approve the Hepatitis C Virus Medication PA form. M. Baack seconded the motion. The motion was approved unanimously.

ADHD Review

The committee asked that ADHD medications be reviewed at the September meeting. There was no public comment. The committee asked that claims for recipients less than 3 be reviewed. No further action was taken.

Juvisync Review

C. Rieth presented clinical information on Juvisync. This topic was tabled.

Narrow Therapeutic Index Drugs

C. Rieth presented information on narrow therapeutic index drugs. This topic was tabled.

New Oral Anticoagulants Review

C. Rieth presented clinical information for new oral anticoagulants. A. Nicholas, representing Boehringer Ingelheim, spoke regarding Pradaxa. J. Stoffel, representing Janssen Scientific Affairs, spoke regarding

Xarelto. A motion was made by J. Engelbrecht to place oral anticoagulants on prior authorization. R. Holm seconded the motion. The motion passed unanimously.

ODT Review

C. Rieth presented information for orally disintegrating tablets currently available. There was no public comment. The committee asked that more information be brought to the March meeting

The next meeting date is scheduled for March 2, 2012. The location will be updated on the website as soon as possible. A motion was made by B. Ladwig at 2:50pm to adjourn the SD Medicaid P&T meeting. D. Farver seconded the motion. Motion passed unanimously and the meeting was adjourned.